@ARTICLE{Kiseleva, author = {Kiseleva, Irina and Stepanova, Ekaterina and Krutikova, Elena and Donina, Svetlana and Rekstin, Andrey and Bazhenova, Ekaterina and Pisareva, Maria and Katelnikova, Anastasia and Kryshen, Kirill and Muzhikyan, Arman and Grigorieva, Elena and Rudenko, Larisa and }, title = {Could Trivalent LAIV Protect Against Both Genetic Lineages of Influenza B Virus?}, volume = {6}, number = {1}, abstract ={Introduction: The global co-circulation of two influenza B virus genetic lineages known as B/Yamagata and B/Victoria may lead to a mismatch between the circulating virus and the strain recommended for use in influenza vaccines. Little is known about the protective efficacy of unmatched influenza B strains, especially when it comes to live attenuated influenza vaccine. The main purpose of this study was to demonstrate the viability of using live attenuated influenza vaccine developed on B/USSR/60/69 backbone to protect from heterologous influenza B challenge infection. Methods: To estimate the potential cross-protective activity of mono- and trivalent live attenuated vaccines based on B/Victoria or B/Yamagata genetic lineage virus against a heterological challenge. Ferrets were given one dose of vaccine and then challenged with influenza B virus and monitored for clinical signs associated with influenza infection. Samples of the ferrets’ airways were tested for the presence of challenge virus. Results: Mono- and trivalent live attenuated influenza vaccines were shown to be safe and cross-protective against genetically different influenza B viruses based on virological and histological data and clinical signs. A lower titer of heterologous challenge virus in the airways of vaccinated ferrets compared to mock-vaccinated animals inoculated with challenge virus was detected. Interestingly, B/Victoria-based vaccines were more cross-protective compared with B/Yamagata-based vaccines. Conclusion: In the case of mismatches of B component of the trivalent live attenuated influenza vaccine and lineage of the circulating influenza B viruses, one of the options could be using trivalent preparation containing a B/Victoria lineage component. }, URL = {http://vacres.pasteur.ac.ir/article-1-163-en.html}, eprint = {http://vacres.pasteur.ac.ir/article-1-163-en.pdf}, journal = {Vaccine Research}, doi = {10.29252/vacres.6.1.13}, year = {2019} }